My take on the new coming indications: (just put Asthma, Arthritis, Dementia, Parkinson's disease, Alzheimer's aside..)
1. Referring to AGM Presentation December 2020
"ATL1102 New Indications"
Next Steps•
Several inflammatory muscle disease indications(like DMD) have been identified which may benefit from similar CD49d
cell modulation for better treatment outcomes, with animal and ex vivo studies of patient samples in the planning for 2021
• Also
the broader effects of CD49d modulation by ATL1102 are to be studied by analyzing DMD patient plasma samples to
identify potential additional immune modulation mechanisms that may be relevant in the treatment of other diseases
with this experimental work scheduled for 1H 2021
2. Annual Report 2020 (Page 4 -5)
"
ATL1102 for Multiple Sclerosis (MS) and other inflammatory indications"
Multiple Sclerosis (MS) is a life-long, chronic disease that
progressively destroys the central nervous system (CNS). It affects approximately 400,000 people in North America and more than 1 million worldwide. It is a disease that affects more women than men, with onset typically occurring
between 20 and 40 years of age. Symptoms of MS may include vision problems, loss of balance, numbness, difficulty walking and paralysis. In
Australia MS affects over 15,000 people.
3. Positive results in DMD unlock the broader value creation potential of ATL1102 ( ASX announcement on 06-02-2020)
- ATL1102 was previously shown to be
highly effective in reducing MS inflammatory brain lesions in a Phase IIa clinical trial in Relapsing Remitting -MS patients. .... The Company is consulting with clinical experts on the appropriate next steps for clinical development in
MS while also re-engaging with pharmaceutical companies active in the MS space to discuss partnering opportunities. The Company is following up potential sources for non-dilutive grant funding for a Phase IIb clinical trial of ATL1102 in MS patients.
By definition: Central Nervous System (CNS): brain and spinal cordBesides Becker MD/ Limb-girdle(LGMD), the next new indication might include the following MD:
a) Myotonic (MMD)
b) Congenital (CMD)
Hopefully we will have the answer prior to FDA meeting on 19-04-2021...
